Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kyowa Kirin CoTSE:4151 -1.00%85 OCF Margin % is 17.22% as of Jun. 2026, which is 5% below its 10-year median of 18.14. GuruFocus rates TSE:4151 with a GF Score™ of 85/100 and a GF Value™ of 円2,814.40 (Modestly Undervalued). Among 987 Drug Manufacturers companies, Kyowa Kirin Co ranks better than 86.83% on this metric.
The historical data trend for Kyowa Kirin Co's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Kyowa Kirin Co's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kyowa Kirin Co OCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kyowa Kirin Co's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Kyowa Kirin Co's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kyowa Kirin Co (TSE:4151) has a OCF Margin % of 17.22% as of Jun. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Kyowa Kirin Co and its competitors. This is near median its historical median of 18.14. Over the past decade, Kyowa Kirin Co's OCF Margin % has ranged from 12.22 to 26.13. According to the industry distribution chart, Kyowa Kirin Co ranks #130 out of 987 companies in the Drug Manufacturers industry, placing it in the top 13.2%.
Is Kyowa Kirin Co's OCF Margin % too high?
Kyowa Kirin Co's current OCF Margin % of 17.22% is near median its 10-year median of 18.14. Over the past 10 years, this metric has ranged from a low of 12.22 to a high of 26.13. The Drug Manufacturers industry median OCF Margin % is 9.88. Kyowa Kirin Co's value of 17.22% is 74.3% above this industry median. Based on the distribution chart, Kyowa Kirin Co ranks #130 out of 987 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Kyowa Kirin Co has a GF Score™ of 85/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kyowa Kirin Co's OCF Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Kyowa Kirin Co ranks #130 out of 987 companies for OCF Margin %. This places Kyowa Kirin Co in the top 13% of its industry — outperforming the majority of peers. The industry median OCF Margin % is 9.88. Kyowa Kirin Co's value of 17.22% is 74.3% above this benchmark. Historically, Kyowa Kirin Co's own OCF Margin % has ranged from 12.22 to 26.13 over the past decade. While the company's 10-year median is 18.14 vs. the industry median of 9.88, Kyowa Kirin Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Drug Manufacturers company?
The median OCF Margin % among Drug Manufacturers companies is 9.88, based on 987 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kyowa Kirin Co's current OCF Margin % of 17.22% is 74.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Kyowa Kirin Co and its competitors. For the Drug Manufacturers industry, the median OCF Margin % is 9.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kyowa Kirin Co's current OCF Margin % is 17.22%, which is near median its own 10-year median of 18.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kyowa Kirin Co stock overvalued right now?
Based on GuruFocus' analysis, Kyowa Kirin Co (TSE:4151) is currently considered Modestly Undervalued. The stock's GF Value™ is 円2,814.40, compared to a current price of 円2,218.50 — trading 21.2% below its estimated fair value. The current OCF Margin % is 17.22%, which is near median its 10-year median of 18.14 and 74.3% above the Drug Manufacturers industry median of 9.88. Kyowa Kirin Co's overall GF Score™ is 85/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Kyowa Kirin Co (TSE:4151), the current OCF Margin % is 17.22% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kyowa Kirin Co (TSE:4151) Overvalued in 2026?
Based on GuruFocus' analysis, Kyowa Kirin Co stock appears to be undervalued.
The current stock price of 円2,218.50 is trading 21.2% below its estimated GF Value™ of 円2,814.40.
GuruFocus considers Kyowa Kirin Co to be Modestly Undervalued.
Key valuation signals for TSE:4151:
OCF Margin %: 17.22% (near median its 10-year median of 18.14)
GF Value™: 円2,814.40 vs. price of 円2,218.50 (21.2% below fair value)
Industry Position: 74.3% above the Drug Manufacturers median (#130 of 987)
No single metric tells the full story. See the TSE:4151 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kyowa Kirin Co Ltd is engaged in research, development, manufacturing, sales, import and export of prescription pharmaceuticals. Its products include KHK4083/AMG 451, rocatinlimab; ziftomenib; OTL-203 KK8398, infigratinib; KHK4951, tivozanib; OTL-201; KK4277; KK2260; KK2269; KK2845; and KK8123.
85GF Score
Get the complete analysis for TSE:4151
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4151 has been successfully added to your 
